3 Big New Catalysts for Psychedelics Stocks in 2024

Since mid-2021, biotech companies developing medicines based on psychoactive molecules like LSD and psilocybin (more commonly referred to as psychedelics) have had a rough go. Stocks of most of the segment's leaders are down more than 75% compared to three years ago, and for a time, funding for early-stage businesses looked like it was drying up.2024 is going to be different. In fact, there's reason to believe that investors should prepare for takeoff, and also that there are opportunities in store for thos ...